)
Hyderabad-based Suven Life Sciences Limited (Suven) has secured two product patents, one from Japan and another from the US, corresponding to its new chemical entities (NCEs) for the treatment of neurodegenerative diseases. The patents are valid through 2028 and 2029.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents that are useful in the treatment of cognitive impairment associated with disorders like Alzheimer’s, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia, the company stated in a release on Friday.
With the new patents, Suven has a total of six patents from Japan and 12 from the US. These patents are stated to be exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase I or Phase II.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents that are useful in the treatment of cognitive impairment associated with disorders like Alzheimer’s, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia, the company stated in a release on Friday.
With the new patents, Suven has a total of six patents from Japan and 12 from the US. These patents are stated to be exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase I or Phase II.
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS (central nervous system) arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally” Suven chief executive officer, Venkat Jasti, said.
